Compare Peptides

Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.

Popular comparisons

Lactoferrin

Lactotransferrin, LF

Unregulated
Immune & Antimicrobial

Thymosin Alpha-1

Tα1, Zadaxin

Category 1
Immune Support
Overview

A naturally occurring iron-binding glycoprotein found in milk, saliva, tears, and mucosal secretions. One of the body's first-line innate immune defenses. Available as an oral supplement and in research-grade injectable form.

A thymic peptide that plays a central role in immune system regulation. Approved as a drug in over 35 countries (though not in the US) for hepatitis B and C treatment and as an immune booster.

Mechanism of Action

Binds free iron, depriving bacteria of a nutrient essential for growth (bacteriostatic effect). Also directly disrupts bacterial cell membranes (bactericidal). Modulates immune response by promoting T-cell and NK cell activity while reducing inflammatory cytokines. Enhances iron absorption in the gut.

Enhances T-cell function, promotes dendritic cell maturation, and modulates cytokine production. Acts as an immune system regulator rather than a simple stimulant, helping to balance immune responses.

Common Uses
  • Immune support
  • Iron deficiency (improves absorption)
  • Gut health
  • Antimicrobial defense
  • Anti-inflammatory support
  • Immune system support
  • Chronic infection management
  • Cancer adjunct therapy (in some countries)
  • Post-illness recovery
  • Autoimmune condition management
Known Risks
  • Generally well-tolerated orally
  • GI discomfort at high doses
  • Allergic reactions in dairy-sensitive individuals
  • Injectable form has limited safety data
  • Generally well-tolerated in clinical use
  • Injection site reactions
  • Rare allergic reactions
  • May interact with immunosuppressive drugs
Regulatory Status
Unregulated

Available as a dietary supplement (GRAS status). Not FDA-approved for any medical indication. Widely available OTC. Injectable form is research-only.

Category 1

Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Approved as Zadaxin in 35+ countries but not FDA-approved in the US. Available through licensed 503A compounding pharmacies with a physician prescription.

This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.